HeartBeam Expands Commercial Presence Across Four Key U.S. Markets with Addition of Premier Concierge Practice

(Moderate)

(Very Positive)

Key Terms

concierge medical practice technical

A concierge medical practice is a primary-care clinic that charges patients an ongoing membership fee or retainer in exchange for faster access, longer appointments, direct doctor contact, and more personalized care; doctors carry fewer patients so they can spend more time with each. For investors, it matters because the model replaces fee-for-service unpredictability with predictable subscription revenue and often higher margins, but it can limit growth speed and addressable patient volume—think of it like a premium subscription versus a mass-market service.

preventive cardiology medical

Preventive cardiology is the branch of medicine focused on reducing the risk of heart disease through early detection, lifestyle changes, medications, and monitoring—like routine maintenance that keeps a car running smoothly to avoid breakdowns. For investors, it matters because successful prevention can lower long-term healthcare spending, shift demand toward diagnostics, monitoring tools and outpatient services, and change revenue patterns for drugmakers, device makers, insurers and healthcare providers.

3d ecg medical

A 3D ECG is an advanced way of recording the heart’s electrical activity that creates a three-dimensional map instead of the usual flat tracing, like turning a paper map into a 3D model to see depth and direction. For investors, it signals a diagnostic product or service that can improve detection and localization of heart problems, potentially commanding premium pricing but also facing regulatory approval, clinical validation and adoption hurdles that affect commercial prospects.

12-lead ecg medical

A 12-lead ECG (electrocardiogram) is a common medical test that records the heart’s electrical activity from 12 different viewpoints using sensors on the chest and limbs—like taking a multi-angle snapshot of the heart’s rhythm and signals. It matters to investors because it is a routine tool for detecting heart problems and monitoring safety in clinical trials and product use; abnormal findings can influence regulatory decisions, trial outcomes, or a healthcare company's market value.

arrhythmia medical

An arrhythmia is an irregularity in the heart’s normal rhythm, where the heartbeat is too fast, too slow, or uneven—like a drummer losing the beat and throwing off a song. It matters to investors because arrhythmias drive demand for drugs, medical devices, and tests; clinical trial results, regulatory approvals, safety alerts, or shifts in how common they are can quickly change a healthcare company's sales, costs, and stock outlook.

subscription-based business model financial

A subscription-based business model charges customers a recurring fee—weekly, monthly or annually—for ongoing access to a product or service rather than a one-time purchase. Investors care because steady, repeat payments create more predictable revenue and customer relationships, similar to a gym membership that provides regular cash flow and clearer growth visibility; that predictability affects valuation, cash planning and how risky the business looks.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

05/07/2026 - 08:31 AM

Leading concierge practice Atelier Health, led by physicians affiliated with Cedars-Sinai, will now offer HeartBeam to its patients
Opens up flagship sites across New York, Dallas, South Florida and Southern California, supporting scalable expansion of HeartBeam technology in preventive cardiology
HeartBeam continues to execute on its go-to-market strategy in high-value, direct-pay care environments

SANTA CLARA, Calif.--(BUSINESS WIRE)-- HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced a commercial agreement with Atelier Health, a premier concierge medical practice led by physicians affiliated with Cedars-Sinai Medical Center. The addition of Beverly Hills-based Atelier Health expands HeartBeam’s commercial footprint across four targeted launch markets – New York metro, Dallas, South Florida, and Southern California – completing an initial geographic footprint to advance the Company’s scalable go-to-market strategy in concierge and preventive cardiology.

The collaboration underscores HeartBeam’s positioning within the high-value direct pay healthcare segment where adoption of innovative technologies can occur more rapidly and patients are seeking proactive cardiac insights tailored to their individual risk profiles. Through its recently announced partnership with ClearCardio™, the Company has also established its initial presence in New York metro, Dallas, and South Florida. Atelier Health extends the network to Southern California, establishing HeartBeam’s initial commercial footprint across its targeted launch markets and providing a foundation for broader national expansion.

Atelier Health, which is expanding its Beverly Hills presence with enhanced imaging capabilities and rebranding as Generational Health, offers individualized preventive and diagnostic programs supported by advanced medical protocols, specialist-level access and world-class technology. Co-founder Ram Dandillaya, MD, who previously served as Clinical Chief of Cardiology at Cedars-Sinai for 8 years, and his patients previously participated in HeartBeam’s Early Access Program, gaining firsthand experience with the Company’s patented cable-free 3D ECG technology. By capturing the heart’s electrical signals in three non-coplanar dimensions and synthesizing them into a 12-lead ECG, HeartBeam enables patients to obtain high-fidelity, clinical-grade ECG data for arrhythmia assessment from the comfort of home.

“Prevention is foundational to how we care for patients, which requires access to high-quality, meaningful data beyond the clinic,” said Dr. Dandillaya. “Our model is built on delivering the highest standard of specialist care with unmatched access and precision, and HeartBeam’s technology enables a more proactive, personalized approach to evaluating cardiac symptoms in real-world settings.”

“The addition of Atelier Health reflects the growing momentum behind our commercialization strategy,” said Robert Eno, Chief Executive Officer of HeartBeam. “With flagship sites now established across our initial launch markets, we are building a strong foundation for scalable growth. We believe partnering with leading concierge and preventive cardiology practices will continue to accelerate adoption of the HeartBeam System and expand access to clinical-grade cardiac insights beyond traditional care settings.”

This partnership advances HeartBeam's commercialization strategy across the concierge and preventive cardiology segment while validating its subscription-based business model. With multiple customers now established across key geographies, HeartBeam is building a repeatable model designed to support broader national expansion.

About Atelier Health

Atelier Health is a concierge medical practice based in Beverly Hills, California, delivering specialist-led healthcare with a focus on personalized prevention and treatment. The practice provides patients with 24x7x365 access to expert care, offering individualized programs supported by advanced medical protocols and world-class technology. Atelier Health’s physicians are affiliated with Cedars-Sinai Medical Center, which has been recognized by U.S. News & World Report as one of America’s Best Hospitals. Atelier Health’s mission is to deliver compassionate, family-centered care while providing patients access to the highest standard of U.S.-based specialty medicine. Visit https://atelier90210.com/ for more information.

About HeartBeam, Inc.

HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company has developed the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-Lead ECG synthesis software received FDA clearance for arrhythmia assessment in December 2025¹. The Company holds over 20 issued patents related to technology enablement. For additional information, visit HeartBeam.com.

Forward-Looking Statements

All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

¹Cleared Indications for Use

The HeartBeam System with 12-Lead ECG synthesis software is FDA cleared for arrhythmia assessment. Refer to the Company’s Cleared Indications for Use at https://www.heartbeam.com/indications for details on the intended use of its technology.

MKT-143 v0